Third-Line Treatment Options for Metastatic Colorectal Cancer - Episode 2

Nuances With Defining “Refractory” mCRC in the Third-Line Setting

November 21, 2024

Marwan G. Fakih, MD, City of Hope, Nilo Azad, MD

Panelists discuss how “refractory” metastatic colorectal cancer (mCRC) is defined in the third- vs fourth-line setting, and the treatment goals in the third-line setting, focusing on optimizing patient outcomes and managing progression after prior therapies.

EP. 1: Navigating mCRC: Treatment Options in the Third-Line Setting

Now Viewing

EP. 2: Nuances With Defining “Refractory” mCRC in the Third-Line Setting

EP. 3: Treatment Sequencing in mCRC: Balancing Expert Perspectives and Shared Decision-Making With Patients

EP. 4: Perspectives on the SUNLIGHT Trial: Study Design and Outcomes

EP. 5: Factoring in Health-Related Quality of Life Outcomes in mCRC Treatment Selection

EP. 6: Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab

EP. 7: Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment

EP. 8: Unmet Needs in Third-Line mCRC: Challenges and Opportunities

How do you define “refractory” mCRC in the third- vs fourth-line setting, and what are your treatment goals in the third-line setting?